Transplant Biomarkers
Transplant Biomarkers - Related Videos
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
0 Views •
Cited by 14 •
2012
High throughput validation of multiple candidate biomarkers can be performed by sequential ELISA in order to minimize freeze/thaw cycles and use of precious plasma samples. Here, we demonstrate how to sequentially perform ELISAs for six different validated plasma biomarkers1-3 of graft-versus-host disease (GVHD)4 on the same plasma sample.
08:15
Cervical Heterotopic Mouse Heart Transplantation using End-to-side Anastomosis Technique to Study Transplant Immunology
0 Views •
2026
This protocol presents a simplified, end-to-side suture anastomosis technique for murine cervical heart transplantation, providing a robust and reproducible model for studying transplant immunology.
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
11:29
A Modified Method for Heterotopic Mouse Heart Transplantion
0 Views •
Cited by 5 •
2014
A technique is demonstrated for the microsurgical procedure for heterotopic transplantation of hearts in mice, including simplified methods for donor harvesting and recipient vessel anastomosis.
07:59
Murine Full-thickness Skin Transplantation
0 Views •
Cited by 41 •
2017
Murine full-thickness skin transplantation is a well-established model to study rejection in an alloimmune setting. Here, we provide a tutorial of each step involved in performing a BALB/c-->C57BL/6 full-thickness skin transplant.
FAQs
Interpretation depends on which biological process a marker reflects. Signals associated with alloimmune activation can inform assessment of rejection, whereas markers linked to infection may point toward transplant-associated infectious complications; indicators of tissue injury or graft function address additional causes of dysfunction. This separation helps investigators compare competing explanations rather than treating every abnormal result as rejection.
Donor-derived cell-free DNA is informative because its origin connects the measured nucleic acid signal to the transplanted organ. When evaluated alongside indicators of graft function, immune activity, or tissue injury, it can contribute to assessment of processes affecting the graft. Its value in transplant research is therefore tied to interpreting donor-specific signal within the broader biological context.
Blood, urine, and tissue provide different windows into post-transplant biology. Measuring proteins, nucleic acids, immune-cell profiles, or metabolites in these materials allows investigators to examine different biological signals. The chosen source affects which aspect of graft function, immune activity, tissue injury, or infection can be assessed and should match the research question.
Serial changes can support monitoring because they show whether a biological signal is shifting after transplantation. A result can therefore be considered in relation to evolving graft function, immune activity, tissue injury, or infection rather than as an isolated measurement. This time-oriented use may help identify emerging problems earlier than clinical findings alone and inform individualized care.
Researchers select a relevant biological source and measurement category, then assess signals such as proteins, nucleic acids, donor-derived cell-free DNA, immune-cell profiles, or metabolites. Results are interpreted with graft function, immune activity, tissue injury, infection, and clinical findings. This workflow supports monitoring, risk prediction, and investigation of graft dysfunction.
Biomarker results can contribute biological evidence when researchers or clinicians evaluate immunosuppressive management. Signals related to alloimmune activation or other graft processes may help assess whether treatment decisions align with the patient's current biological state. Their role is to support individualized transplant care and help distinguish immune-mediated dysfunction from infection or injury when those possibilities compete.
Beyond detecting current graft problems, transplant biomarkers can support risk prediction and patient monitoring. Their measurements may help estimate risk related to rejection, infection, immune activity, or graft injury, while also supporting individualized care. In research, this predictive role complements immediate assessment and helps connect biological measurements with longer-term transplant-care decisions.